Kaiser adds to payer ire over Sovaldi price

Share this article:

Kaiser Permanente, the big HMO, is swallowing the cost of Gilead's hepatitis C treatment Sovaldi, but is angry about the $84,000 cost.

“It's an outrageous price for a therapy that has huge public health implications,” associate director of the Permanente Medical Group Sharon Levine tells Reuters. Levine says that the medication will be what Reuters described as a “material portion of its drug budget,” even with a discounted rate.

The drugmaker has been criticized by lawmakers and others, but this is not new territory for Gilead. The company has also been grilled over the cost of its Stribild HIV medication, among others.

Gilead has claimed that Sovaldi's high price trades short-term financial burden for long-term savings by helping patients avoid later expenses, such as those associated with liver failure.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.